−0.9336USD
−5.15 MUSD
13.27 MUSD
15.38 M
About Sonoma Pharmaceuticals, Inc.
Sector
CEO
Amy M. Trombly
Headquarters
Boulder
Website
Employees (FY)
171
Founded
1999
ISIN
US83558L2043
FIGI
BBG000M75YR0
Sonoma Pharmaceuticals, Inc. engages in the development and production of hypochlorous acid (HOCl) products for wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of SNOA is 0.17 USD — it has increased by 1.27% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sonoma Pharmaceuticals, Inc. stocks are traded under the ticker SNOA.
Sonoma Pharmaceuticals, Inc. is going to release the next earnings report on Jul 10, 2024. Keep track of upcoming events with our Earnings Calendar.
SNOA earnings for the last quarter are −0.20 USD whereas the estimation was −0.19 USD which accounts for −5.46% surprise. Estimated earnings for the next quarter are −0.21 USD. See more details about Sonoma Pharmaceuticals, Inc. earnings.
Sonoma Pharmaceuticals, Inc. revenue for the last quarter amounts to 2.73 M USD despite the estimated figure of 3.60 M USD. In the next quarter revenue is expected to reach 3.76 M USD.
Yes, you can track Sonoma Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, SNOA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sonoma Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 171.00 employees. See our rating of the largest employees — is Sonoma Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sonoma Pharmaceuticals, Inc. EBITDA is −4.10 M USD, and current EBITDA margin is −32.19%. See more stats in Sonoma Pharmaceuticals, Inc. financial statements.